BMS' Opdivo Is Too Expensive, Says NICE
Executive Summary
NICE has again said no to Bristol-Myers Squibb's Opdivo, this time for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults already treated with chemotherapy. The company had suggested different pricing proposals to try and make the drug more cost-effective, but it may fare better if it focuses on certain patient populations.